A new generation of biotech companies is rapidly advancing the antibody landscape, fueled by strong early-stage funding and a focus on differentiated therapeutic strategies. Across modalities, from bispecific antibodies and ADCs to single-domain antibodies, shuttle systems, and half-life extension, these emerging players are not only expanding the scope of what antibodies can target, but also how they function in complex disease settings.
These companies are building platform-driven approaches that integrate novel biology with engineering innovation. Whether enabling targeted protein degradation, improving intracellular delivery, or enhancing specificity and durability, the goal is to overcome long-standing limitations in efficacy, safety, and druggability.
Seed Round: $68.7 million | Date: March 18, 2026
Excalipoint Therapeutics launched to advance T cell engagers, including a tri-specific antibody for small cell lung cancer and neuroendocrine tumors. Their technologies (e.g. TOPAbody, Immune Shield, Probody-based TCEs) enable multispecific and conditionally active antibodies that enhance tumor targeting and address challenges such as “cold” tumors and difficult-to-drug antigens.
Seed Round: €17 million | Date: March 20, 2026
Laigo Bio is advancing targeted protein degradation therapies. Their SureTACs™ platform, which uses bispecific antibodies to selectively eliminate disease-causing membrane proteins. By pairing target proteins with E3 ligases, the approach induces precise ubiquitination and lysosomal degradation, enabling dual-targeted removal of pathogenic proteins. They aim to develop therapies in oncology and autoimmune diseases.
Series A: $112.5 million | Date: January 14, 2026
Caldera Therapeutics launched to develop a first-in-class bispecific antibody CLD-423 for inflammatory bowel disease. The molecule simultaneously targets the IL-23p19 and TL1A pathways. By combining two clinically validated mechanisms into a single molecule, the approach is designed to enhance efficacy, optimize pharmacokinetics, and improve safety compared to existing therapies.
Series A: $50 million | Date: March 3, 2026
Prolium Bioscience launched and announced first patients Dosed with PRO-203, a CD20xCD3 T-cell engager, for severe autoimmune disease. It works by inducing targeted B-cell depletion by bridging CD20+ B cells and CD3+ T cells to drive T-cell–mediated cytotoxicity, enabling deep and potentially durable immune reset. Potential indications include systemic sclerosis and lupus.
Series B: $107 million | Date: January 8, 2026
EpiBiologics to advance pipeline of novel bispecific antibodies to selectively degrade extracellular and membrane-bound disease drivers in oncology and immunology. Their modular EpiTAC system enables precise degradation of pathogenic proteins directly at the disease site. They aim to deliver therapies across oncology and immunology, including mutation-agnostic strategies against targets such as EGFR.
Seed Round: $13 million | Date: January 26, 2026
Fortitude Biomedicines launched to advance immune cell targeting biologics and molecular glue payload-enabled ADCs for autoimmune diseases and cancer, combining immune cell-targeting biologics with a proprietary ADC platform. Its GLUE-DAC™ technology involves molecular glue-mediated protein degradation, aiming to overcome resistance, expand target scope, and improve therapeutic efficacy.
Financing Round: $120 million | Date: November 17, 2025
Solve Therapeutics is advancing a pipeline of next-generation ADCs for solid tumors with its proprietary CloakLink hydrophilic linker system and a focus on selectively expressed tumor antigens. CloakLink is engineered to mask the hydrophobic properties of ADC payloads, enabling enhanced plasma stability, improved pharmacokinetics, reduced toxicity, and potent tumor cell killing. The result is a class of ADCs with higher therapeutic indices and improved overall performance.
Series B: $137 million | Date: April 8, 2026
Sidewinder Therapeutics is developing next-generation bispecific ADCs designed to expand the therapeutic window through enhanced tumor specificity and internalization. Their bsADCs are designed to target receptor co-complexes that are highly expressed on certain solid tumors, such as an oncogenic driver receptor and an internalizing receptor. They aim to advance their lead program into clinical development in 2027.
Series A + Extension: $95 million | Date: March 3, 2026
Poplar Therapeutics to advance anti-IgE therapies for multiple atopic conditions. Their lead candidate, PHB-050, features a unique triple-action mechanism that not only prevents IgE from triggering allergic responses but also reduces circulating IgE levels and inhibits its production. PHB-050 is a humanized camelid single-domain (VHH) IgG1 Fc-fusion antibody that binds soluble IgE. This approach aims to address limitations of existing therapies with more durable control of IgE-mediated conditions such as food allergy, asthma, and atopic dermatitis.
Series A: $10 million | Date: November 11, 2025
IBI Ag leverages single-domain antibodies to create biological insect control products. Adapted from the pharmaceutical field and optimized for agriculture, their platform introduces new modes of action that protect high-value crops from both sucking and chewing insects, while minimizing environmental impact and preserving beneficial species.
Seed Round + Extension: €9 million | December 22, 2025
Lever Bio to develop four novel VHH antibody-based therapies targeting key metabolic and immunological pathways in the tumor microenvironment. By leveraging metabolic and immune system reprogramming, the company aims to overcome resistance mechanisms to existing cancer therapies, particularly in solid tumors. Their compounds target components of the solid tumor microenvironment, including PlexinA4, SCL4A4, and P2Y6, to foster anti-cancer immune response enhancing the recruitment, activation and sustained function of cytotoxic T lymphocytes against solid tumors.
Seed Round: €9 million | Date: March 17, 2026
iDEL Therapeutics launched to advance cancer pipeline (a single-domain antibody and multicancer drug conjugate) by enabling direct delivery of therapeutics into the cytosol of tumor cells. Its proprietary shuttle technology bypasses endosomal entrapment, allowing both large and small molecules to reach and engage intracellular targets that have historically been undruggable.
Series A: $150 million | Date: February 18, 2026
Korsana Biosciences emerged from stealth, developing next-generation shuttled mAb targeting amyloid beta for treatment of neurodegenerative diseases. Their THETA™ platform, a transferrin receptor (TfR1)-based approach designed to overcome limitations of earlier shuttle technologies for delivery of biologics across the blood–brain barrier. They aim to create treatments for Alzheimer’s and other CNS disorders.
Series A: $130 million | Date: February 24, 2026
Slate Medicines launched to advance therapies for the prevention of migraine and other headache disorders by targeting PACAP (pituitary adenylate cyclase-activating polypeptide), a clinically validated pathway distinct from CGRP. Its lead program, SLTE-1009, is an mAb with extended half-life. Slate aims to expand preventive options and improve efficacy in migraine care.
Series A: $90 million | February 14, 2025
Bambusa Therapeutics to advance next-generation half-life extended bispecific antibodies for immunology and inflammation diseases, designed to target complementary disease-driving signaling pathways, affording the potential for a best-in-disease profile for patients. Two of Bambusa’s four programs are on track to enter the clinic in Q1 2025 and mid-2025, respectively.
Learn how multivalent and bispecific VHH antibodies are engineered, their advant……
April 2026 activity saw consolidation in the ADC space, continued expansion of n……
Read on for key trends talked about during the conference: Antibody Therapeutics……
Explore VHH antibody humanization strategies, challenges, and validation methods……
You can also contact us on the Scientist and Science Exchange marketplaces.
